Identification of SLC15A3 as a shared prognostic biomarker for AML and COVID-19 via integrative bioinformatics, machine learning and Mendelian randomization
- 1College of Basic Medicine, Beihua University
- 2College of Public Health, Beihua University
Abstract
Acute myeloid leukemia (AML) is a lethal hematological malignancy with poor overall prognosis.COVID-19 co-infection further complicates clinical management and worsens survival outcomes of AML patients, highlighting the need to explore the molecular interplay between the two diseases. In this study, we initially screened 109 common differentially expressed genes shared by AML and COVID-19 from public transcriptomic datasets, which were closely involved in tumor progression and viral pathogenesis. We further characterized their biological functions, constructed protein interaction and TF-miRNA regulatory networks, and established an AML prognostic model to evaluate the tumor immune microenvironment. Combining survival analysis, clinical correlation, immune infiltration assessment and m ⁶ A modification analysis, SLC15A3 was preliminarily screened as a candidate prognostic gene for AML. Subsequent weighted gene co-expression network analysis (WGCNA), machine learning (ML) and Mendelian randomization (MR) analyses further identified SLC15A3 as a promising prognostic biomarker for AML. Finally, RT-qPCR and Western blotting assays verified its aberrant expression in AML cells. Consistent with bioinformatic prediction, SLC15A3 serves as a shared candidate biomarker for AML and COVID-19,although its mechanistic role linking AML and SARS-CoV-2-related inflammation requires further functional validation.
Related
- Identification of Genes Associated with Gut Microbiota Metabolites in Type 2 Diabetes Mellitus Complicated by Acute Cerebral Infarction Based on Bioinformatics and Mendelian Randomization
- Integrative Multi-Database Bioinformatics Characterization of FANCE in Hepatocellular Carcinoma: Prognostic, Epigenetic, Immune, and ncRNA Associations
- Integrative Bioinformatics and Machine Learning Approaches for Biomarker and Pathway Discovery in Malignant Pleural Mesothelioma
- Comprehensive Pan-Cancer Bioinformatics Analysis Identifies DHX58 as a Promising Therapeutic Target and Prognostic Biomarker Across Multiple Tumor Types
- Identification of transcriptomic signatures associated with an ac4C related gene set and candidate expression based clusters in osteoarthritis through integrative bioinformatics
BibTeX
@article{liu2026identification,
title = {{Identification of SLC15A3 as a shared prognostic biomarker for AML and COVID-19 via integrative bioinformatics, machine learning and Mendelian randomization}},
author = {Miaomiao Liu and Junhui Zhu and Huan Li},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1911550},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1911550/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Identification of SLC15A3 as a shared prognostic biomarker for AML and COVID-19 via integrative bioinformatics, machine learning and Mendelian randomization
AU - Miaomiao Liu
AU - Junhui Zhu
AU - Huan Li
PY - 2026
DA - 2026/10/14
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1911550
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1911550/full
AB - Acute myeloid leukemia (AML) is a lethal hematological malignancy with poor overall prognosis.COVID-19 co-infection further complicates clinical management and worsens survival outcomes of AML patients, highlighting the need to explore the molecular interplay between the two diseases. In this study, we initially screened 109 common differentially expressed genes shared by AML and COVID-19 from public transcriptomic datasets, which were closely involved in tumor progression and viral pathogenesis. We further characterized their biological functions, constructed protein interaction and TF-miRNA regulatory networks, and established an AML prognostic model to evaluate the tumor immune microenvironment. Combining survival analysis, clinical correlation, immune infiltration assessment and m ⁶ A modification analysis, SLC15A3 was preliminarily screened as a candidate prognostic gene for AML. Subsequent weighted gene co-expression network analysis (WGCNA), machine learning (ML) and Mendelian randomization (MR) analyses further identified SLC15A3 as a promising prognostic biomarker for AML. Finally, RT-qPCR and Western blotting assays verified its aberrant expression in AML cells. Consistent with bioinformatic prediction, SLC15A3 serves as a shared candidate biomarker for AML and COVID-19,although its mechanistic role linking AML and SARS-CoV-2-related inflammation requires further functional validation.
SN - 2234-943X
ER -